Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Ironwood Pharmaceuticals (IRWD) over the last 8 years, with Q3 2025 value amounting to $27.9 million.

  • Ironwood Pharmaceuticals' Tax Provisions rose 10359.98% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 1296.75%. This contributed to the annual value of $64.3 million for FY2024, which is 2297.25% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Tax Provisions stood at $27.9 million, which was up 10359.98% from $14.2 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Tax Provisions ranged from a high of $32.1 million in Q4 2023 and a low of -$336.9 million during Q2 2021
  • In the last 5 years, Ironwood Pharmaceuticals' Tax Provisions had a median value of $16.7 million in 2022 and averaged -$3.1 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Tax Provisions surged by 399722.22% in 2022 and then plummeted by 8778.51% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Tax Provisions (Quarter) stood at $4.9 million in 2021, then surged by 377.55% to $23.4 million in 2022, then soared by 37.18% to $32.1 million in 2023, then tumbled by 32.34% to $21.7 million in 2024, then grew by 28.65% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $14.2 million for Q2 2025, and $1.1 million during Q1 2025.